Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.40 |
| ▸ | F11 | P03951 | 16/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 15/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | KLK1 | P06870 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30702184 | 1.00 | NOTUM (0.40) | NOTUMF11KLKB1CYP3A4KLK1 | |
| SCHEMBL17302638 | 0.82 | NOTUM (0.43) | NOTUMF11KLKB1CYP3A4KLK1 | |
| SCHEMBL16983100 | 0.82 | RXRA (0.42) | NOTUMF11KLKB1CYP3A4KCNH2 | |
| SCHEMBL17661915 | 0.80 | NOTUM (0.41) | NOTUMF11KLKB1CYP3A4KCNH2 | |
| SCHEMBL30379474 | 0.80 | NOTUM (0.45) | NOTUMF11KLKB1CYP3A4KCNH2 | |
| SCHEMBL15060116 | 0.80 | NOTUM (0.45) | NOTUMF11KLKB1CYP3A4KCNH2 | |
| SCHEMBL17479438 | 0.79 | NOTUM (0.38) | NOTUMF11KLKB1CYP3A4 | |
| SCHEMBL30702222 | 0.79 | NOTUM (0.39) | NOTUMF11KLKB1CYP3A4KCNH2 | |
| SCHEMBL20360397 | 0.79 | NOTUM (0.39) | NOTUMF11KLKB1CYP3A4KCNH2 | |
| SCHEMBL25260390 | 0.78 | OPRM1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737457-A1 | POLYSUBSTITUTED MACROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-20250282748-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-09-11 | — | — | US | disclosed |
| WO-2025002297-A1 | POLYSUBSTITUTED MACROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳信立泰药业股份有限公司 | 2025-01-02 | — | — | WO | disclosed |
| CN-113292539-B | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20230024752-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230024752-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| WO-2022222960-A1 | FXIA INHIBITOR AND PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND USE THEREOF | 上海美悦生物科技发展有限公司 | 2022-10-27 | — | — | WO | disclosed |
| EP-3368036-B1 | MACROCYCLIC PYRIDINE-N-OXIDE DERIVATIVES AS FACTOR XIA INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2022-07-20 | — | — | EP | disclosed |
| US-11180471-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-11-23 | — | — | US | disclosed |
| US-11180471-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-11-23 | — | — | US | disclosed |
| US-10421742-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-09-24 | — | — | US | disclosed |
| US-10421742-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-09-24 | — | — | US | disclosed |
| US-20180339977-A1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-11-29 | — | — | US | disclosed |
| EP-3368036-A1 | FACTOR XIA INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20180194745-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-12 | — | — | US | disclosed |
| US-20180194745-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-12 | — | — | US | disclosed |
| US-20180194745-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-12 | — | — | US | disclosed |
| US-9868727-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170210732-A1 | Factor XIa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-07-27 | — | — | US | disclosed |
| WO-2017074832-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10421742-B2 | Substituted oxopyridine derivatives | OGFOD1, VASP, PNPO | NOTUM 2289/4885F11 928/4885KLKB1 2656/4885 |
| US-11180471-B2 | Substituted oxopyridine derivatives | OGFOD1, VASP, PNPO | NOTUM 2289/4885F11 928/4885KLKB1 2656/4885 |
| US-20180194745-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, VASP, PNPO | NOTUM 2289/4885F11 928/4885KLKB1 2656/4885 |
| US-20170210732-A1 | Factor XIa Inhibitors | F11, SERPINC1, TFPI | NOTUM 757/4885F11 1/4885KLKB1 14/4885 |
| US-20250282748-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, VASP, PNPO | NOTUM 2289/4885F11 928/4885KLKB1 2656/4885 |
| US-20230024752-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, VASP, PNPO | NOTUM 2289/4885F11 928/4885KLKB1 2656/4885 |
| US-20180339977-A1 | FACTOR XIA INHIBITORS | F11, SERPINC1, TFPI | NOTUM 757/4885F11 1/4885KLKB1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.